Drug Detail

Information about TAE226

Generic Name	TAE226
IND	TAE226
Brand Name (US)
Manufacturer	Novartis
Drug Type	Tyrosine Kinase Inhibitor
Delivery	Oral
Approval Status	Preclinical
Indications
Overall Strategy	GIST cell based
Strategy	Block related tumor signal paths
Drug Category	IGF1R inhibitor + FAK inhibitor

IGF1R has been shown to be overexpressed in wild-type GISTs and pediatric GISTs (which are typically "wild-type" as well). The importance of IGF-1R is not as clear for KIT and PDGFRA mutant GIST.
Inhibition of focal adhesion kinase (FAK) has also been suggested as a therapeutic target in GIST.
TAE226 is an oral drug in preclinical development. It is manufactured by Novartis. It inhibits both IGF1R and FAK.